肺癌患者先天[18F]氟脱氧葡萄糖PET骨网络预测生存
本研究回顾性分析多中心ACRIN 6668试验中34例不可手术的IIIB期非小细胞肺癌(NSCLC)患者的数据,在放化疗前后进行肺部及骨骼的常规FDG PET SUV分析和骨网络分析。结果显示,常规肺肿瘤SUV峰值分析不能预测生存(p=0.23-0.35),而放化疗前骨葡萄糖代谢网络分析可显著预测生存(p=0.0003)并识别三个生存亚组。放化疗后网络预测价值丧失(p=0.77)。
要点
- 放化疗前骨葡萄糖代谢网络分析可显著预测NSCLC患者生存(p=0.0003)。
- 常规肺肿瘤SUV峰值分析不能预测NSCLC患者生存(p=0.23-0.35)。
- 放化疗后骨网络预测价值丧失(p=0.77),与治疗前网络不同。
核心结论
- NSCLC患者治疗前先天骨骼葡萄糖代谢网络可预测生存,而治疗后适应的网络则不能,支持骨骼在先天免疫和全身葡萄糖代谢调节中的作用。
- 新提出的网络分析优于常规SUV PET分析,作者认为应考虑将其作为NSCLC患者管理中的预后工具。
研究设计与样本
- 本研究为对多中心试验ACRIN 6668数据的回顾性分析,纳入34例不可手术的IIIB期NSCLC患者。
- 在放化疗前后对肺部病灶和骨骼进行常规[18F]FDG PET SUV分析以及骨骼网络分析。
主要发现
- 常规肺肿瘤SUV峰值分析不能预测NSCLC患者生存(p=0.23-0.35)。
- 放化疗前骨葡萄糖代谢网络分析可显著预测患者生存(p=0.0003),并识别三个不同的生存者集群(短期、长期和混合期)。
- 放化疗导致先天生存者集群均质化为适应的混合期集群,骨葡萄糖代谢网络的预测价值丧失(p=0.77)。
临床怎么用
- 作者认为,新提出的网络分析优于常规SUV PET分析,应考虑作为NSCLC患者管理中的预后工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prognostication of lung cancer patients remains challenging clinically. This study aims to address this problem by investigating the utility of bone glucose metabolism networks as a prognostic biomarker of lung cancer patients. The rationale for targeting bone metabolic networks specifically comes from the long-recognised role of bone in innate immunity and the recent appreciation of the key role bones play in regulating whole-body glucose metabolism. METHODS: This study is a retrospective analysis of data from the multi-centre trial ACRIN 6668 on non-small cell lung carcinoma (NSCLC). Conventional [18F]Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) standardised uptake value (SUV) analysis of lung lesions and bones as well as network analysis of bones were carried out in 34 stage IIIB non-operable NSCLC patients before and after chemoradiation. RESULTS: Conventional lung tumour SUV peak analysis of PET data cannot predict NSCLC patient survival (p = 0.23-0.35), while network analysis of bone glucose metabolism pre-chemoradiation can significantly predict patient survival (p = 0.0003) and identify three distinct clusters of survivors (short-term, long-term and mix-term). Chemoradiation treatment results in homogenisation of the innate survivors' clusters into adapted mix-term clusters and loss of predictive value of bone glucose metabolism networks (p = 0.77). CONCLUSIONS: Innate pre-treatment skeletal glucose metabolism networks of NSCLC patients can predict patient survival in contrast with adapted post-treatment networks, supporting the role of bones in both innate immunity and regulation of systemic glucose metabolism. Newly proposed network analysis performs better than conventional SUV PET analysis, and should be considered as a prognostication tool in the management of NSCLC patients.
引用
- Ronghe R, Crespo Gonzalez T, Wimberley C, et al. Innate [18F]Fluorodeoxyglucose PET bone networks of lung cancer patients predict survival. Eur J Nucl Med Mol Imaging. 2025. PMID: 40471319. doi:10.1007/s00259-025-07388-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。